Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Repligen's enterprise value was $8.93B on Nov 11, 2026, against $8.88B a year earlier. Over the last 5 years it ranged from $5.87B to $14.02B, with a median of $8.42B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.93B | +5.4% |
| 2025 | Dec 31, 2025 | $8.47B | +16.4% |
| 2024 | Dec 31, 2024 | $7.28B | -22.5% |
| 2023 | Dec 29, 2023 | $9.40B | +6.5% |
| 2022 | Dec 30, 2022 | $8.83B | -37.0% |
| 2021 | Dec 31, 2021 | $14.02B | +47.2% |
| 2020 | Dec 31, 2020 | $9.53B | +122.0% |
| 2019 | Dec 31, 2019 | $4.29B | +102.2% |
| 2018 | Dec 31, 2018 | $2.12B | +49.4% |
| 2017 | Dec 29, 2017 | $1.42B | +60.6% |
| 2016 | Dec 30, 2016 | $884.77M | +0.1% |
| 2015 | Dec 31, 2015 | $883.89M | +44.5% |
| 2014 | Dec 31, 2014 | $611.61M | +64.5% |
| 2013 | Dec 31, 2013 | $371.89M | +158.5% |
| 2012 | Dec 31, 2012 | $143.88M | +151.1% |
| 2011 | Dec 30, 2011 | $57.29M | -56.5% |
| 2010 | Dec 31, 2010 | $131.70M | – |
See a number that looks wrong?